Generics - Oncology


Current filters:


Popular Filters

76 to 95 of 95 results

Bayer challenges Indian ruling on Nexavar patent


German drug major Bayer (BAYN: DE) has launched an appeal against the Indian Patent Office, which a couple…


Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too


Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Cancer drugs shortages persist in Poland


In Poland, the recent procurement problems of cancer drugs is far from solved, writes Sebastian Gensior…


India issues compulsory license for Bayer cancer drug Nexavar


The Indian Patent Office has issued the first-ever compulsory licence in India to a generic drug manufacturer.…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Sandoz initiates two more Phase III biosimilar trials


Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…


Hospira progresses biosimilar Epogen


USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

Amgen in cancer biosimilars deal with Watson


A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

NSCL cancer drug market set to grow 2.5% a year between 2010 and 2020, despite generic erosion


Despite the arrival of generic competition – and ensuing sales erosion for several key agents used…

GenericsMarkets & MarketingOncologyPharmaceutical

Actavis to boost oncology presence in Turkey, with generic drug launches


Iceland-headquartered generic drugmaker Actavis is planning to increase its presence in Turkey next year…

ActavisEuropeGenericsMarkets & MarketingOncology

Strides Arcolab gets two more cancer generics approved in USA


Onco Therapies, a wholly owned subsidiary of Indian generics drugmakers Strides Arcolab (BO: 532531),…

CarboplatinGenericsMarkets & MarketingNorth AmericaOnco TherapiesOncologyOxaliplatin InjectionPfizerRegulationStrides Arcolab

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region


Canada’s AEterna Zentaris (TSX: AEZ) has signed an exclusive commercialization and licensing agreement…

AEterna ZentarisGenericsHikma PharmaceuticalsLicensingOncologyperifosinePharmaceuticalRest of the World

Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report


By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

Mylan enters settlement and license deal with Roche over Xeloda


US generic drugs giant Mylan (Nasdaq: MYL) says that it has entered into a settlement and license agreement…

GenericsLegalLicensingMylan LaboratoriesNorth AmericaOncologyRocheXeloda

Glycotope enrolls first patient for “biobetter” of Roche cancer drug Herceptin


Berlin, Germany-based glycomics specialist Glycotope GmbH says it has enrolled the first patients in…


76 to 95 of 95 results

Back to top